臨床検査53巻13号

2009年12月発行

今月の主題 前立腺癌 総論

前立腺癌の診断手順と治療の選択

著者： 田中宣道¹ 平尾佳彦¹

所属機関： ¹奈良県立医科大学泌尿器科

ページ範囲：P.1641 - P.1648

　前立腺特異抗原(PSA)の登場以来，前立腺癌の診断・治療は大きく変化し，限局性前立腺癌の占める割合は飛躍的に増加してきた．現在，従来の根治的前立腺全摘除術に加えて3D-CRTやIMRTなどの外部照射，密封小線源治療や高線量率ブラキセラピーなどの組織内照射などの放射線治療，さらにPSA監視療法など多岐にわたる治療選択が可能となっている．本稿では，前立腺癌の診断手順と，治療法の選択について概説する．

参考文献

1) Cooperberg MR, Lubeck DP, Mehta SS, et al：Time trends in clinical risk stratification for prostate cancer：implications for outcomes(data from CaPSURE). J Urol　170：S21-S27, 2003

2) Ries LA, Melbert D, Krapcho M, et al(eds)：SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/(2009年9月1日参照)

3) Carter BS, Bova GS, Beaty TH, et al：Hereditary prostate cancer：epidemiologic and clinical features. J Urol　150：797-802, 1993

4) 福多史昌，舛森直哉，田中吉則，他：下部尿路症状を主訴とする受診症例における前立腺癌発見率．臨泌　59：133-138，2005

5) Tanaka N, Fujimoto K, Chihara Y, et al：Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for prostate cancer patients with intermediate PSA levels. Prostate Cancer Prostatic Dis　10：274-278, 2007

6) Dutkiewicz S, Stepieú K, Witeska A：Bladder catheterization and a plasma prostate-specific antigen in patients with benign prostatic hyperplasia and complete urine retention. Mater Med Pol　27：71-73, 1995

7) 西谷真明，西村和重，高木紀人：尿閉患者の前立腺癌診断における前立腺特異抗原/γ-セミノプロテイン比(P/S Ratio)測定の有用性の検討．日泌尿会誌　86：1368-1374，1995

8) McNeill SA, Hargreave TB：Efficacy of PSA in the detection of carcinoma of the prostate in patients presenting with acute urinary retention. J R Coll Surg Edinb　45：227-230, 2000

9) Oesterling JE, Jacobsen SJ, Chute CG, et al：Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA　18：860-864, 1993

10) Ito K, Yamamoto T, Kubota Y, et al：Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. Urology　56：278-282, 2000

11) Egawa S, Suyama K, Takashima R, et al：Prospective evaluation of prostate cancer detection by prostate-specific antigen-related parameters. Int J Urol　6：493-501, 1999

12) Tanaka N, Fujimoto K, Yoshikawa M, et al：Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer. Hinyokika Kiyo　53：459-465, 2007

13) Hodge KK, McNeal JE, Terris MK, et al：Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol　142：71-75, 1989

14) EAU Guideline 2009：http://www.uroweb.org/nc/professional-resources/guidelines/online/(2009年9月1日参照)

15) 前立腺癌診療ガイドライン 2006年版(日本泌尿器科学会編)，金原出版，pp51-52，2006

16) AUA Guideline；Prostate―specific Antigen Best Practice Statement：Revised(2009)：http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm(2009年9月1日参照)

17) Partin AW, Mangold LA, Lamm DM, et al：Contemporary update of prostate cancer staging nomograms(Partin Tables)for the new millennium. Urology　58：843-848, 2001

18) Kattan MW, Eastham JA, Stapleton AM, et al：A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst　90：766-771, 1998

19) Clinicopathological Research Group for Localized Prostate Cancer Investigators, Naito S, Kuroiwa K, Kinukawa N, et al：Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading：data from the Clinicopathological Research Group for Localized Prostate Cancer. J Urol　180：904-909, 2008

20) Kakehi Y, Kamoto T, Shiraishi T, et al：Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol　38：122-128, 2008

21) AUA Guideline；Management of clinically Localized Prostate Cancer：Revised(2007)：http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm(2009年9月1日参照)

22) Cahlon O, Zelefsky MJ, Shippy A, et al：Ultra-high dose(86.4 Gy)IMRT for localized prostate cancer：toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys　71：330-337, 2008

23) D'Amico AV, Chen MH, Renshaw AA, et al：Androgen suppression and radiation vs radiation alone for prostate cancer：a randomized trial. JAMA　299：289-295, 2008

24) Galalae RM, Kovács G, Schultze J, et al：Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys　52：81-90, 2002

25) Zelefsky MJ, Kuban DA, Levy LB, et al：Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys　67：327-333, 2007

26) Stone NN, Potters L, Davis BJ, et al：Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys　73：341-346, 2009

27) Cancer Registration Committee of the Japanese Urological Association：Clinicopathological statistics on registered prostate cancer patients in Japan：2000 report from the Japanese Urological Association. Int J Urol　12：46-61, 2005

28) Akaza H：Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer：Japanese perspective. Cancer Sci　97：243-247, 2006

29) Fukagai T, Namiki TS, Carlile RG, et al：Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int　97：1190-1193, 2006

30) 平成20年簡易生命表(男)：厚生労働省；http://www.mhlw.go.jp/toukei/saikin/hw/life/life08/xls/seimei.xls(2009年9月1日参照)

31) Sylvester JE, Grimm PD, Blasko JC, et al：15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy；Seattle experience. Int J Radiat Oncol Biol Phys　67：57-64, 2007

32) Robinson JW, Moritz S, Fung T：Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Oncol Biol Phys　54：1063-1068, 2002

33) Nieder AM, Porter MP, Soloway MS：Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer：a population based cohort study. J Urol　180：2005-2010, 2008

34) Roehl KA, Han M, Ramos CG, et al：Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3, 478 consecutive patients：long-term results. J Urol　172：910-914, 2004

35) Kupelian PA, Potters L, Khuntia D, et al：Radical prostatectomy, external beam radiotherapy ＜72 Gy, external beam radiotherapy＞ or＝72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys　58：25-33, 2004

36) Bolla M, Collette L, Blank L, et al：Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer(an EORTC study)：a phase Ⅲ randomised trial. Lancet　360：103-108, 2002

37) Pilepich MV, Winter K, Lawton CA, et al：Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase Ⅲ RTOG 85-31. Int J Radiat Oncol Biol Phys　61：1285-1290, 2005

38) Hussain M, Tangen CM, Higano C, et al：Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer：data from Southwest Oncology Group Trial 9346(INT-0162). J Clin Oncol　24：3984-3990, 2006